In this study, we evaluate Venture Labs' enzyme-linked immunosorbent assay (ELISA) for the detection of methadone in postmortem specimens. Sixty-one postmortem specimens that previously screened positive for methadone along with 59 specimens which screened negative for methadone were included. All specimens were screened using the Venture Labs methadone assay in conjunction with a liquid-liquid basic extraction and gas chromatographic-mass spectrometric (GC-MS) analysis. All cases screening positive by either method were confirmed for methadone and its metabolite 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine by a solid-phase extraction utilizing deuterated internal standards and GC-MS-SIM. Twenty-four postmortem samples that screened negative by both methods were also extracted and analyzed using the confirmation method to demonstrate the validity of both screening methods. The intra-and interassay precision for the ELISA method was evaluated at the cut-off concentration used for the analysis (50 ng/mL). True positives, true negatives, false positives, and false negatives were calculated for the ELISA results as compared to the GC-MS screening data. The Venture Labs methadone assay demonstrated a sensitivity of 96.7% + 2.3% and a specificity of 98.3% • 1.7% relative to the GC-MS method.
and gas chromatography-mass spectrometry (GC-MS) full scan qualitative analysis in postmortem blood.
The objective of this study was to test the suitability of the Venture Labs (Redwood City, CA) solid-phase enzyme immunosorbent assay specific for methadone in the routine screening of postmortem samples. Results for specimens tested by the Venture Methadone Assay TM were compared to results from an alkaline drug screen by gas chromatography-mass spectrometry (GC-MS). The precision of the Venture assay was determined, along with sensitivity, specificity, and predictive value.
Introduction
Our laboratory currently receives approximately 80 cases per week from 2 submitting locations (Boston and Holyoke) of the Commonwealth of Massachusetts Office of the Chief Medical Examiner (OCME) in Massachusetts. Recently, different investigators have noted the increased prevalence of methadone use and abuse (1) (2) (3) (4) . The increased abuse of methadone may represent a continuum of a pattern which began with the abuse of controlled-release oxycodone and other prescription drugs (1) . In response to the apparent increase in both licit and illicit encounters with methadone in postmortem cases, our laboratory incorporates rapid presumptive testing for the drug in blood by enzyme-linked immunosorbent assay (ELISA). The new ELISA screening technology complements our existing strategies for presumptive testing in urine by immunoassay * Author to whom correspondence should be addressed,
Venture methadone assay
The Venture Labs methadone assay (a solid-phase enzyme immunosorbent assay using microtiter plates) was evaluated. The manufacturer supplied the calibration and control bloods used on each plate. A cut-off value of 50 ng/mL of methadone was selected based on toxicological significance and the semitivity of the methadone confirmation method. The positive blood control was set at twice the cut-off concentration (100 ng/mL).
Each OCME case is initially analyzed for six different drugs/drug classes in blood (cocaine, opiates, methadone, benzodiazepines, fentanyl, and oxycodone) on one microplate (2 strips/drug). This configuration includes 3 controls along with 13 case samples analyzed per plate. Although each case was analyzed for all six drugs/drug classes, only the methadone data is presented herein. Thirty microliters of each blood sample (neat) was pipetted into the appropriate wells; 75 IJL of the supplied enzyme reagent (horseradish peroxidase labeled with methadone) was added to each well using an 8-channel pipetter. The plate was then incubated at room temperature for 30 rain. Following the incubation, the plate was hand-rinsed using running tap water to remove all traces of blood. The plate was then washed five times with deionized water on a Thermo Wellwash (Thermo Electron Corp., Waltham, MA), followed by one wash with phosphate buffer/ Tween 20. One-hundred microliters of the substrate/chromogen reagent (peroxide and tetramethylbenzidine) was then added to each well and incubated at room temperature for 15 rain. Following the incubation, 50 pL of the stop solution (3N hydrochloric acid) was added, and the plates were read at 450 nm on a Thermo Multiskan EX. Cases were considered positive if the optical density measured for the case sample was less than or equal to the optical density measured for the cut-off blood.
Assay precision
Intra-assay precision for the methadone ELISA procedure was determined for both the fortified 50 ng/mL cut-off blood and the negative blood by analyzing 45 replicates. Interassay precision for both bloods was determined through three successive analyses over two weeks (n = 189).
Methadone screen by GC-MS
Each case received from OCME was analyzed by full scan GC-MS following liquid-liquid extraction. Two milliliters of blood was added to 16-ram x 125-mm borosilicate glass screw-top tubes along with the internal standard (methapyrilene), 2 mL of saturated sodium borate, and 7 mL of the extracting solvent [toluene/hexane/isoamyl alcohol (78:20:2)]. The tubes were mixed by rotating for 10 rain followed by centrifugation at 3000 rpm for 10 rain. The organic layer was transferred to clean 16-ram x 100-ram tubes, and 2 mL of 0.5N sulfuric acid was added. The tubes were rotary mixed for 5 min and centrifuged for 5 rain at 3000 rpm. The organic layer was then aspirated from the tube, and 2 mL of 0.5N sodium hydroxide along with 2 mL of n-butyl chloride were added to each tube. The tubes were again mixed and centrifuged, and the organic layer was transferred to clean 16 x 100 disposable culture tubes and evaporated at < 40~ under nitrogen. The tubes were reconstituted with 50 pL of ethyl acetate and transferred to autosampler vials.
The samples (1 pL) were injected onto a Hewlett-Packard 6890/5973 GC-MS equipped with a capillary column (HP1, 12 m x 0.2-mm i.d., 0.33 lJm) and run in full-scan mode (scan range 40-400). The injector temperature was 250~ and the initial oven temperature was 50~ The oven was initially ramped at 15~ to 150~ followed by a 20~ ramp to 280~ This temperature was held for 8 rain followed by a final ramp of 30~ to 320~ The limit of detection for methadone by this method is 30 ng/mL.
Methadone confirmation by GC-MS
All positive cases by ELISA and/or GC-MS were subsequently confirmed by GC-MS-SIM for the presence and quantity of methadone and its major metabolite. Fifty-nine cases which screened negative for methadone were also analyzed using the confirmation method. The confirmation method employed solid-phase extraction and detected methadone and its major metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). A calibration curve was prepared from drug-free blood at concentrations of 25, 50, 125, 250, 500, and 1000 ng/mL for both compounds. A commercially prepared blood control (UTAK, Valencia, CA) was analyzed with each run both neat and diluted 1:2. To calibrators, controls, and samples, 200 ~L of a 1 ng/IJL solution containing methadone-d9 and EDDP-d3 (Cerilliant Corp, Round Rock, TX) was added as the internal standard.
Four milliliters of water and 2 mL of 0.1M phosphate buffer (pH 6.0) were added to each tube. The tubes were rotated for 10 min followed by centrifugation at 3000 rpm for 10 min. SPE was performed using United Chemical Technologies' Clean Screen (Bristol, PA) columns following manufacturer recommendations. Briefly, the columns were conditioned with a 3-mL methanol wash, a 3-mL deionized water wash, and a 2-mL 0.1M phosphate buffer (pH 6.0) wash. The samples were applied to the column and permitted to flow by gravity. The columns were then rinsed with 3 mL of deionized water, 1 mL of 0.1M acetic acid, and 3 mL of methanol. Next, the columns were allowed to dry, under vacuum, for l0 min to ensure complete removal of all moisture. The compounds were then eluted with methylene chloride/isopropanol/ammonium hydroxide (78:20:2) and evaporated to dryness under N2. The samples were reconstituted with 150 lJL of ethyl acetate and transferred to GC-MS autosampler vials.
The samples (1 IJL) were injected onto a Hewlett-Packard 6890/5973N GC-MS equipped with a capillary column (HP-5MS, 30 m x 0.25-mm i.d., 0.25 ~m) and run in selected-ionmonitoring mode (SIM). The injector temperature was 270~ and the initial oven temperature was 140~ The oven was initially ramped at 30~
to 255~ followed by a 5~ ramp to 270~ and finally by a 30~ ramp to 300~ This temperature was held for I min. Methadone ions monitored were 72, 223, and 294. Methadone-d9 internal standard ions monitored were 78 and 303. EDDP ions monitored were 277, 262, and 278. EDDP-d3 internal standard ions monitored were 280 and 265.
Sensitivity and specificity
In this study, the GC-MS screen was considered the "true" condition status and the Venture ELISA screen was the "test" condition. True positives (cases positive by both ELISA and GC-MS = TP), true negatives (cases negative by both ELISA and GC-MS = TN), false positives (positive by ELISA and negative by GC-MS = FP), and false negatives (negative by ELISA and positive by GC-MS = FN) were determined for each of the 120 cases. Sensitivity, the probability that the ELISA method will detect methadone provided methadone is present, was calculated as TP/(TP + FN). Specificity, the probability that the ELISA method will not detect methadone provided methadone is not present, as TN/(FP + TN). Positive predictive value, the probability that a sample is positive for methadone when a positive test result is observed, as TP/(TP + FP). And negative predictive value, the probability that a sample is negative for methadone when a negative test result is observed, as TN/ (TN + FN) . The standard error for each probability was calculated using SE = q[p * (1 -p)]/n, where p is the calculated probability and n is the sample number (5).
Results

Precision
The intra-assay precision of the Venture Labs Methadone Assay (n ---45) for the 50 ng/mL fortified blood was OD 0.715 with a calculated percent coefficient of variation (%CV) of 5.8%; for blank blood, OD 1.491 with a 5.2% CV. The interassay precision (n = 189) for the 50 ng/mL fortified blood was OD 0.658 with a 12.8% CV; for blank blood, OD 1.555 with a 5.5% CV. Table I are the qualitative results for each screening assay (Venture and GC-MS) for the 61 methadone positive cases and the resulting quantitative values for the confirmation GC-MS method. From this table, the TPs and TNs and the FPs and FNs were tallied and summarized in Table  II . The sensitivity, specificity, and predictive values were calculated as described here. At the chosen cut-off of 50 ng/mL, the ELISA method had a sensitivity of 96.7% _+ 2.3%, a specificity of 98.3% _+ 1.7%, a positive predictive value of 98.3% _+ 1.7, and a negative predictive value of 96.7% _+ 2.3%. Shown in Table III are structurally similar compounds to methadone and their relative cross-reactivity for the assay, which were confirmed by our laboratory (6) .
Case results
Shown in
Discussion
There were two FNs in this study in which the Venture ELISA failed to detect methadone while the GC-MS analysis had detected the drug. However, for both of these cases, methadone was subsequently quantitated below the cut-off concentration (50 ng/mL) for the ELISA method. Because of the GC-MS screen's lower limit of detection (30 ng/mL), it is not surprising that the ELISA method did not screen positive. When the ODs were further analyzed for those specific cases, it was noted that the methadone OD, although higher than the cut-off, was much lower than negative blood. The manufacturer has stated that 2 ng/mL is the lowest concentration the assay is capable of detecting (6). Thus, there was methadone in the sample being detected, but it was not sufficient to surpass the blood cut-off. The one FP in this study also had a concentration of methadone that was confirmed to be below the cutoff value; however, in this case, the ELISA had a positive result, but the GC-MS screen was negative. Further review of the case indicated that methadone was present in the GC-MS screen; however, the integration parameters were set such that the methadone peak was not initially integrated. The small methadone peak was identified on the GC-MS data only after retrospective review given the positive ELISA result.
Conclusions
The Venture Labs Methadone Assay performed well in the screening of postmortem specimens for methadone. It demonstrates comparable results to the traditional GC-MS alkali-extracted drug screen, but is more time efficient and requires no organic solvents. Furthermore, the Venture assay needs no sample preparation or manipulation and uses minimal specimen volume (30 ]~L) per assay.
